ARENA PHARMAC (NASDAQ:ARNA)

View All ReportsStreetInsider.com Reports on ARNA

Nov 10, 2009 06:45 AM Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of $0.38, Misses by 4c

Nov 6, 2009 01:29 PM Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report

Oct 26, 2009 07:30 AM Arena Pharma (ARNA) Reports Pivotal BLOOM Phase III data

Oct 12, 2009 08:49 AM Obesity 2009 to Feature Multiple Presentations of Arena Pharma's (ARNA) Lorcaserin

Sep 21, 2009 06:53 AM Leerink Swann Downgrades Arena Pharmaceuticals (ARNA) to Market Perform

View All Press ReleasesCompany Press Releases on ARNA

Nov 18, 2009 06:50AM StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.

Nov 9, 2009 07:06PM Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments

Nov 4, 2009 04:08PM Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009

Oct 27, 2009 10:40AM New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life

Oct 25, 2009 06:21PM Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with

StreetInsider Reports on ARNA by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on ARNA

Nov 10, 2009 03:07 PM Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript

Nov 10, 2009 07:19 AM Wall Street Breakfast: Must-Know News

Nov 4, 2009 09:55 AM Options Trader: Wednesday Outlook, Fed Edition

Nov 3, 2009 11:14 AM Amylin Takes Lead in Obesity Race

Nov 3, 2009 09:44 AM Options Trader Testy Tuesday Outlook: Dow 9,650, Berkshire $60 Edition

View All FilingsSEC Filings on ARNA

Nov 10, 2009 06:16AM Form 8-K ARENA PHARMACEUTICALS For: Nov 09

Nov 9, 2009 05:26PM Form 10-Q ARENA PHARMACEUTICALS For: Sep 30

Oct 30, 2009 04:31PM Form 8-K ARENA PHARMACEUTICALS For: Oct 30

Oct 21, 2009 05:05PM Form 8-K/A ARENA PHARMACEUTICALS For: Jun 17

Comments on recent ARNA articles

chris
on Mar 17, 2009
at 02:08 AM SEC The SEC doesnt investigate. They are only a cleanup crew. Witness B Maddoff, who, despite hundreds of tips over 5 years, was not turned in until the economy tanked.
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks

JAC47
on Mar 16, 2009
at 06:12 PM ARNA Analysis The Canaccord analysist must have missed the ARNA business presentation slide 54 (December 2008) below. The FDA required the first phase III Bloom Trial to exclude those with Valvulopathy. However, the FDA allowed patients with existing valvulopathy in the Second pahse III Blossum Trial. They would not have done that if there was any significant signs of risk in the Bloom Trial. Bad call by an analyst with a BA in economics. • BLOOM – 3,182 patients randomized 1:1 during Year 1 to receive placebo or lorcaserin 10 mg BID – Echoes performed at Screening, 6, 12, 18 and 24 months – Patients with FDA valvulopathy excluded – Echo-DSMB reviewed all echoes from 6 and 12 months (unblinded)— differences, if any, between placebo and lorcaserin group were not meaningful • BLOSSOM – 4,008 patients randomized 2:1:2, placebo: lorcaserin 10 mg QD: lorcaserin 10 mg BID – Echoes performed at Baseline, 6 and 12 months – No echo exclusion criteria; FDA valvulopathy allowed – Data will be combined with BLOOM data for integrated analysis with sufficient statistical power to address negotiated endpoint
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks

wasl
on Mar 16, 2009
at 02:07 PM ARNA This is the broker that obviously is behind the dubious naked shorts, should be investigated by sec!
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks

Comments on ARNA

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?